S80123
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海源葉生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/5/16 7:38:14
- 訪問(wèn)次數(shù) 157
聯(lián)系方式：何小姐15921386130 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
生物試劑,ELISA試劑盒,對(duì)照品,標(biāo)準(zhǔn)品,培養(yǎng)基,透析袋,病理科耗材,實(shí)驗(yàn)室耗材
- 提示：詳情請(qǐng)下載說(shuō)明書(shū),。
- 產(chǎn)品描述： Avagacestat (BMS-708163) is a potent inhibitor of γ-secretase, with IC50s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with IC50 of 0.84 nM and shows weak inhibition of CYP2C19, with IC50 of 20 μM. Avagacestat can be used for Alzheimer disease research.
- 靶點(diǎn)： IC50: 0.27 nM (γ-secretase, Aβ42), 0.30 nM (γ-secretase, Aβ40), 20 μM (CYP2C19), 0.84 nM (NICD)
- 體內(nèi)研究： Avagacestat (BMS-708163) significantly reduces both plasma and brain Aβ40 levels relative to control at 10 and 100 mg/kg for the entire dosing interval, demonstrates significant Aβ40 lowering for 8 h after an oral dose of 1 mg/kg, and significantly lowers CSF Aβ40 levels in rats, when measured 5 h after single oral doses ranging from 3 to 100 mg/kg. Avagacestat (BMS-708163) (10?mg/kg) monotherapy has a minor inhibitory effect on PC9/AB2 tumor growth compared with gefitinib alone. BMS-708163 monotherapy results in a slight increase in caspase 3 expression as well as a mild decrease in Ki-67 expression in vivo. In the xenograft lung cancer samples treated with Avagacestat (BMS-708163) plus gefitinib, there are a marked increase in caspase 3 expression and a reduction in Ki-67 staining
- 參考文獻(xiàn)：
1. Gillman KW, et al. Letter Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. Med Chem Lett, 2010, 1 (3), 120-124. 2. Xie M, et al. γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer. J Cell Biochem. 2015 Jun;116(6):1019-27. 3. Crump CJ, et al. BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry. 2012 Sep 18;51(37):7209-11. 4. Borghys H, et al. A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators. J Alzheimers Dis. 2012;28(4):809-22. 5. Vladimir Coric, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
- 溶解度： Soluble in DMSO
- 保存條件： -20℃
- 配置溶液濃度參考：
1mg 5mg 10mg 1 mM 1.92 ml 9.599 ml 19.198 ml 5 mM 0.384 ml 1.92 ml 3.84 ml 10 mM 0.192 ml 0.96 ml 1.92 ml 50 mM 0.038 ml 0.192 ml 0.384 ml
- 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的性,，僅供客戶參考交流研究之用,。
采購(gòu)中心
化工儀器網(wǎng)